Taysha Gene Therapies (NASDAQ:TSHA) Now Covered by Analysts at BMO Capital Markets

BMO Capital Markets began coverage on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note published on Thursday, MarketBeat.com reports. The brokerage issued an outperform rating and a $5.00 price target on the stock.

A number of other analysts have also weighed in on the company. Jefferies Financial Group restated a buy rating and set a $8.00 target price (up previously from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday, May 14th. Cantor Fitzgerald restated an overweight rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. JMP Securities reiterated a market outperform rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Needham & Company LLC reissued a buy rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Monday, June 17th. Finally, Canaccord Genuity Group reaffirmed a buy rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of Buy and an average price target of $6.80.

Taysha Gene Therapies Stock Up 6.1 %

Shares of TSHA stock opened at $2.17 on Thursday. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.75. Taysha Gene Therapies has a twelve month low of $0.57 and a twelve month high of $4.32. The stock has a fifty day simple moving average of $2.97 and a two-hundred day simple moving average of $2.41.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The company had revenue of $3.41 million during the quarter, compared to analyst estimates of $3.70 million. During the same period in the prior year, the firm earned ($0.28) earnings per share. On average, research analysts expect that Taysha Gene Therapies will post -0.43 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Howard Capital Management Inc. acquired a new position in shares of Taysha Gene Therapies in the 4th quarter valued at $25,000. Victory Capital Management Inc. purchased a new position in shares of Taysha Gene Therapies in the fourth quarter worth about $28,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Taysha Gene Therapies during the fourth quarter worth about $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in Taysha Gene Therapies in the fourth quarter valued at approximately $38,000. Finally, Cannon Global Investment Management LLC acquired a new position in Taysha Gene Therapies in the 1st quarter worth approximately $69,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.